Daily weight-loss pills cannot defend their market share against the extreme convenience of monthly injections.
The clinical emergence of highly effective once-monthly injectable therapies is compressing the commercial potential and valuation models of daily oral metabolic drugs.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Amgen is banking on the competitive advantage of ultra-low dosing intervals to disrupt the dominant weekly therapies in the obesity space.
Pfizer is pivoting its pipeline to capitalize on berobenatide as an ultra-long-acting monthly maintenance injectable designed to challenge weekly and daily therapies.
Pure-play daily oral developers face valuation pressure because they must prove their daily regimens can commercially compete with ultra-convenient monthly injections.
Pfizer is abandoning its early oral pipeline assets to double down on a more convenient, long-acting monthly injectable formulation.
Novo Nordisk is actively developing ultra long-acting semaglutide implants to bypass the adherence challenges inherent to weekly and daily dosing schedules.